Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease
NCT02499783
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
205
Enrollment
INDUSTRY
Sponsor class
Conditions
Crohn's Disease
Interventions
BIOLOGICAL:
adalimumab
OTHER:
placebo
Sponsor
AbbVie